Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.24.1.1.u2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)    
Revenues, net $ 3,620 $ 40,442
Operating expenses:    
Cost of implants and other costs 1,667 8,676
Research and development 213,834 237,387
Selling, general and administrative 750,098 796,049
Impairment of intellectual property 0 47,980
Depreciation and amortization 6,713 6,665
Total operating expenses 972,312 1,096,757
Loss from operations (968,692) (1,056,315)
Other income (expenses):    
Interest expense - related parties (186,828) (169,380)
Interest expense, net (181,820) (26,040)
Grant income 112,963 241,149
Other miscellaneous expense (13,086) 0
Total other (expense) income (268,771) 45,729
Loss before provision for income taxes (1,237,463) (1,010,586)
Income taxes 0 0
Net loss (1,237,463) (1,010,586)
Non-controlling interest 687 934
Net loss attributable to BioCorRx Inc. $ (1,236,776) $ (1,009,652)
Net loss per common share, basic and diluted $ (0.14) $ (0.13)
Weighted average number of common shares outstanding, basic and diluted 8,757,859 7,741,681